​

Sionna Therapeutics Stock (NASDAQ:SION)

ForecastOwnershipFinancialsChart
Sionna Therapeutics by TradingView

Previous Close

$34.03

52W Range

$13.51 - $48.45

50D Avg

$40.16

200D Avg

$36.93

Market Cap

$1.63B

Avg Vol (3M)

$398.15K

Beta

1.29

Div Yield

-

SION Company Profile

Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

41

IPO Date

Feb 07, 2025

Website

SION Performance

SION Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-88.98M$-70.56M$-50.33M
Net Income$-75.27M$-61.69M$-47.26M
EBITDA$-88.98M$-69.89M$-49.75M
Basic EPS$-1.88$-1.40$-1.07
Diluted EPS$-1.88$-1.40$-1.07

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
MAZEMaze Therapeutics, Inc.
XERSXeris Biopharma Holdings, Inc.
ABCLAbCellera Biologics Inc.
BHVNBiohaven Ltd.
CLDXCelldex Therapeutics, Inc.
ZYMEZymeworks Inc.
VERAVera Therapeutics, Inc.
ARDXArdelyx, Inc.
JANXJanux Therapeutics, Inc.
IMNMImmunome, Inc.